Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1424223 | Journal of Controlled Release | 2013 | 9 Pages |
In order to develop a novel kidney-targeted drug delivery system, we synthesized prednisolone carbamate–glucosamine conjugate (PCG) using 2-glucosamine as a ligand, and investigated its potential targeting efficacy. In vitro studies demonstrated that PCG could remarkably improve the uptake of drug by kidney cells. And the specific uptake of PCG could be largely reduced by the inhibitors of megalin receptor. More importantly, PCG showed an excellent kidney targeting property in vivo, and the concentration of the conjugate in the kidney was 8.1-fold higher than that of prednisolone group at 60 min after intravenous injection. Besides, PCG could significantly reverse the disease progression in renal ischemia–reperfusion (I/R) injury animal models. Furthermore, PCG presented no adverse effect on bone density while prednisolone resulted in severe osteoporosis. Thus, it indicated that 2-glucosamine could be a potential ligand for kidney-targeted delivery of prednisolone.
Graphical abstractFigure optionsDownload full-size imageDownload high-quality image (82 K)Download as PowerPoint slide